Navigation Links
SmartCycler 4800 System

ProductsSmartCycler 4800 System
Company Cepheid
Item SmartCycler 4800 System
Features Inquire
Description The SmartCycler System is a rapid, real-time thermal cycler used for identifying DNA/RNA from prepared biological samples. By automating much of the testing process, and making each reaction site individually programmable, it is the fastest, easiest to use, and most flexible system now on the market. The SmartCycler delivers highly accurate and consistent test results in as little as 20 minutes.

Flexible
With up to 96 independently programmable reaction sites, the SmartCycler can simultaneously run multiple experiments with different protocols and at different times. This enables multiple users to use SmartCycler simultaneously. This eliminates complex advanced scheduling on larger, more costly systems as well as the need to transport samples to central facilities for analysis.

Fast
There's no need to wait hours or days for results on other platforms. With capability to perform extremely rapid heating and cooling cycles, the SmartCycler System can deliver results in as little as 20 minutes.

Real-time detection
Each independently programmable module performs four-color, real-time fluorometric detection. Samples are amplified and measured in the SmartCycler's proprietary, sealable reaction tubes that are designed to optimize rapid thermal transfer and optical sensitivity, as well as to reduce the possibility of amplicon contamination.

Four-channel optics
The SmartCycler System enables the detection of several targets within a single sample (multiplex assays) by using multiple fluorescent dyes and detecting the fluorescent signal in four channels. The instrument's optics allow application to the rapidly evolving needs of a molecular biology lab using detection methods including Molecular Beacons and TaqMan probes, Amplifluor and Scorpion primers, and intercalating dyes such as SYBR Green.

Expandable
Users can configure a system to suit their exact needs - with 16, 32, 48, 64, 80 or 96 reaction sites. As testing volumes expand, more sites can be added to a system at any time. The system software enables one or more operators to define and simultaneously carry out separate experiments, each with a unique set of cycling protocols, threshold criteria, and data analysis. Additionally, thermal and optical data can be monitored in real-time, and graphs of temperature, growth, and melt curves are displayed during data collection.

Info Cepheid
Customer Service: (408) 541-4191
Web site: http://www.cepheid.com/

Related medicine products :

1. SmartCycler 1600 System
2. SmartCycler® 6400 System
3. SmartCycler® 3200 System
4. SmartCycler 3200 System
5. SmartCycler 6400 System
6. SmartCycler 9600 System
7. SmartCycler® 8000 System
8. SmartCycler 8000 System
9. Silicone Oil Cannula System - 20 Gauge
10. Silicone Oil Cannula System - 19 Gauge
11. SuperVu Galilean System
... SPECIFICATIONS Appearance/Form: White to buff-colored powder Activity: >=590g of ... (A&B): Passes tests Limit of Methanol: Specific Rotation ... pH (4%, H 2 O): 3.5 to 5.5 Loss ... C 1 : 25-50% C 2 + C ...
Gentamicin is a selection antibiotic used for selection of a Bac-to-Bac recombinant expression bacmid following transposition. Gentamicin is provided as a solution at a concentration of 50 mg/ml....
Gentamicin is an aminoglycosidic antibiotic that inhibits bacterial growth by inhibiting protein synthesis. Gentamicin is used for prevention and elimination of bacterial contaminants in cell culture...
1.0% Tryptone, 0.5% yeast extract, 0.5% Sodium Chloride, 0.6% agarose....
Medicine Products:
(Date:12/6/2009)... Cambridge have discovered that the loss of a key segment ... the first study to show that this kind of genetic ... Nature . , The study, led by Dr Sadaf ... from the Wellcome Trust Sanger Institute, looked at 300 children ... genome looking for types of mutation known as copy number ...
(Date:12/6/2009)... DNA in virus , , SUNDAY, Dec. 6 (HealthDay News) -- ... found in a tiger that lived thousands or millions of ... virus took on a bit of a tiger,s genetic material, ... the virus to this day. That tiger, in fact, may ... virus that ultimately led to its infection of humans. , ...
(Date:12/6/2009)... 6 Onyx Pharmaceuticals, Inc. (Nasdaq: ... the pivotal Phase 2b 003-A1 study, known as ... in heavily pre-treated relapsed and refractory multiple myeloma ... ASH/ASCO Joint Symposium at the 51st annual meeting ... New Orleans. Enrollment in this trial is complete ...
(Date:12/6/2009)... ORLEANS, Dec. 6 Blood clotting, or ... bleeding when a blood vessel is injured. Sometimes, ... without an obvious injury or do not dissolve ... presented today at the 51st Annual Meeting of ... practice of using the anticoagulants aspirin and heparin ...
(Date:12/6/2009)... Internet Sleep Disorders information and Treatment site ... sleep problems with herbal or natural sleep aids ... ,insomnia remedies for a good cause. The submissions ... Natural Sleep Aids ,Encyclopedia, by YOU, to be ... The site will donate 100% of the proceeds ...
Breaking Medicine News(10 mins):Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:AIDS May Date Back to Ancient Tiger 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2
... claim against City of New York and New York City Police ... ... 2008 -- http://thesandersfirm.com/attorney.asp?attorneyid=14 [Marc Grossman], senior partner of leading ... & Grossman, P.C. in Bronx, New York, today announced that his ...
... Calif., Aug. 27 Patient Safety,Technologies, Inc. (PST) (OTC ... $2.325 million in equity financing in a first closing ... enhancing sales and,marketing at its SurgiCount Medical subsidiary. Investors ... shares of the,Company,s common stock at a price of ...
... 27 Replidyne, Inc.,(Nasdaq: RDYN ) today ... employee headcount by approximately 80% to 5 employees ... September 2008 and October,2008. As a result of ... REP3123, its investigational agent for the,treatment of Clostridium ...
... medical students will gain access to innovative medical, ... the first satellite, radio channel created for medical ... ReachMD XM 157 announced today a new,strategic ... the nation,s oldest and largest, independent,association for physicians-in-training., ...
... Nashville, TN Injury prevention experts have long known ... wear seat belts while driving. Now, researchers from the ... lack of seat belt use by teen passengers may ... ever direct comparison of the differences between driver and ...
... insulin-resistant proteins, study says , , WEDNESDAY, Aug. 27 (HealthDay News) ... those in lean people, a new study shows. , ... group of researchers from the Temple University School of Medicine ... and six obese people. , They found significant differences in ...
Other Medicine News:Health News:New York-Based Sanders Law Firm Files Claim for Good Samaritan Beaten by New York City Police Officers 2Health News:Patient Safety Technologies Closes on $2.325 Million in Equity Financing 2Health News:Replidyne Announces Restructuring of Operations 2Health News:ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association 2Health News:ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association 3Health News:Teens making poor choices when it comes to riding in vehicles 2
(Date:12/3/2009)... variation that may indicate a patient,s risk of developing ... pharmaceutical therapies or chemicals is one of several medical ... DGX ) will present during the 51st ... December 5-8, 2009, in New Orleans, LA. ,, ...
(Date:12/3/2009)... Realty Trust, Inc. (NYSE: BMR ) announced today ... Pharmaceuticals, Inc. (Nasdaq: REGN ) for approximately 131,000 square ... Landmark at Eastview campus in Tarrytown, New York. The new ... space was completed approximately two months after BioMed and Regeneron ...
(Date:12/3/2009)... and SAN DIEGO, California, December 3 , ... microRNA Important for,Hepatitis C Viral Replication, Thereby Significantly Reducing ... With the,Hepatitis C Virus , ... Resistance and,No Serious Adverse Events in the Treated Animals ...
Breaking Medicine Technology:Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Researchers believe hormone therapy should not be stopped prior to mammograms 58398 1Researchers believe hormone therapy should not be stopped prior to mammograms 58398 2Excellence in Paediatrics conference line up includes WHO and CDC pandemic speakers 10130 1Excellence in Paediatrics conference line up includes WHO and CDC pandemic speakers 10130 2Gerton Lab determines the composition of centromeric chromatin 10126 1Gerton Lab determines the composition of centromeric chromatin 10126 2